SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

OMXC 20 NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

COMPANY SEARCH RESULT

Genmab: Click to view the issuer\'s details

Last update : 25/05/2014  >View issuer details

2019.11.12 | 20:02 | Permanent Information Releases / Operations

English version HTML (w) Mail

puce Capital Increase in Genmab as a Result of Employee Warrant Exercise - HTML (w)

2019.11.06 | 17:01 | Permanent Information Releases / Sales and Revenues

English version HTML (w) Mail

puce Genmab Announces Financial Results for the First Nine Months of 2019 - HTML (w)

2019.11.06 | 15:19 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Genmab Announces Data to be Presented at 2019 ASH Annual Meeting - HTML (w)

2019.10.30 | 21:31 | Permanent Information Releases / Appointments

English version HTML (w) Mail

puce David Eatwell to Retire as Chief Financial Officer of Genmab - HTML (w)

2019.10.30 | 10:31 | Permanent Information Releases / Calendar

English version HTML (w) Mail

puce Genmab’s Financial Calendar for 2020 - HTML (w)

2019.10.15 | 12:47 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2019 - HTML (w)

2019.10.11 | 20:55 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Grant of Restricted Stock Units and Warrants to Employees in Genmab - HTML (w)

2019.10.01 | 20:14 | Permanent Information Releases / Operations

English version HTML (w) Mail

puce Capital Increase in Genmab as a Result of Employee Warrant Exercise - HTML (w)

2019.09.09 | 15:07 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Genmab and Tempus Enter into Strategic Collaboration Agreement - HTML (w)

2019.08.30 | 07:16 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 137